Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis

Thrombosis and Haemostasis

Volumn 84, Issue 2, 2000, Pages 286-290

  Berry, Christopher N ^a   Visconte, Catherine ^a   Lecoffre, Catherine ^a   Lochot, Sylvette ^a   Girard, Denise ^a  

^a SANOFI   (France)

Author keywords

Argatroban mixed micelles; Rabbit venous thrombosis; Rat venous thrombosis; Tail transection bleeding time

Indexed keywords

ARGATROBAN; ECARIN; HEPARIN; THROMBIN; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOVENOUS SHUNT; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SOLUBILITY; JUGULAR VEIN; MALE; MICELLE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RABBIT; RISK; TAIL; THROMBIN TIME; THROMBOGENESIS; VEIN THROMBOSIS;

EID: 0033864781     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614009     Document Type: Article

References (24)

1. Erikson Bl, Ekman S, Kälebo P, Zachrisson BZ, Bach D, Close P. Prevention of deep-vein-thrombosis after total hip replacement: direct thrombin inhibition with recomhinant hirudin, CGP 39393. Lancet 1996; 347: 635-9.
2. Erikson Bl, Mouret P, Kälebo P, Baue M, Ekman S, Lindbrat S, Bach D, Close P. Recomhinant hirudin, CGP 39393 (Revasc), is more effective than enoxaparin as prophylaxis uf throinboembolic complications in patients undergoing total hip replacement. Haemostasis 1996; 26 (Supplement 3): 624.
3. Okamoto S, Hijikata A, Kikumoto R, Tonomara S, Hara H, Ninomiya K, Maruyama A, Sugano M, Tamao Y. Potent inhibition of thrombin by the newly synthesized arginine derivative no. 805. The importance of stereo-structure of its hydrophobie carboxamide portion. Biochem Biophys Res Commun 1981; 101: 440-6.
4. 2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-arginyl]-2- piperidinecarboxylic acid. Biochemistry 1984; 23: 85-90.
5. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin-or clot-incorporated thrombin: Comparison with heparin and recomhinant hirudin. Thromb Haemost 1994; 72: 381-6.
6. Lunven C, Gauffeny C, Leeoffre C, O'Brien DP, Roome NO, Berry CN. Inhibition by argatroban, a specific lhrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 1996; 75: 154-60.
7. 2). J Jap Coll Angiol 1989; 29: 57-64.
8. Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallen JT, Collen D. Prevention of Platelet-Rich Arterial Thrombosis by Selective Thrombin Inhibition. Circulation 1990; 81: 219-25.
9. Berry CN, Girard D, Lochol S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous. "mixed" and arterial thrombosis, and its effects on the tail transection Weeding time. Br J Pharmacol 1994; 113: 1209-14.
10. Berry CN, Girard D, Girardot C, Lochot S, Lunven C, Visconte C. Antithrombotic activity of argalrohan in experimental thrombosis in the rabbit. Semin Thromb Hemost 1996; 22: 233-41.
11. Duval N, Lunven C, O'Brien DP, Grossel A, O'Connor SE, Berry CN. Antithrombotic actions of the thrombin inhibitor, argatrohan, in a canine model of coronary cyclic flow: comparison with heparin. Br J Pharmacol 1996; 118: 727-33.
12. Schumacher WA, Heran CL, Steinbachcr TE. Low molecular weight heparin (Fragmin) and thrombin active site inhibitor (Argatroban) compared in experimental arterial thrombosis and bleeding time. J Cardiovascular Pharmacol 1996; 28: 19-25.
13. Berry CN, Lunven C, Girardot C, Lechaire I, Girard D, Charles M-C, Ferrari P, O'Brien DP. Ecarin clotting time: a predictive coagulation assay for the antithrombotic activity of argatroban in the rat. Thromb Haemost 1998; 79: 228-33.
14. Wessier S, Reimer SM, Sheps MC. Biologic assay of thrombosis inducing activity in human serum. J Appl Physiol 1959; 14: 943-6.
15. Berry CN, Lunven C, Lecoffre C, Lainée P, O'Connor SE, André F. Roger B, Garrigou-Gadenne D, Rouchouse A, Roome NO, Vivan N. Anticoagulant activity and pharmacokinetic properties of a sub-cutaneously administered mixed micellur formulation of argatroban in experimental animals. Thromb Haemost 2000; 84: 278-85.
16. Iida S, Koniatsu T, Hirano T, Fujimura Y, Nakai H, Kitazawa K, Kumagai Y, Sato T, Hayashi K, Inokuchi K. Pharmacokinetic studies of argatrohan (MD-805) in dogs and rabbits. Blood or plasma level profile, metabolism, excretion and accumulation after single or consecutive administration of argatroban. Oyo Yakuri (Pharmacometrics) 1986; 32: 1117-27.
17. Clarke RJ, Mayo G, Fitzgerald GA, Fitzgerald DA. Combined administration of argatrohan and aspirin in man. Circulation 1991; 83: 1510-9.
18. Verstraete M. Pharmacotherapeutic aspects of unfractionaled and low molecular weight heparins. Drugs 1990; 40: 498-530.
19. Nurmohamed MT, Berekmans RJ, Morrien-Salomons WM, Bercnds F, Hammes WD, Rijnierse JJMM, Sturk A. Monitoring anticoagulant therapy by activated partial thromboplastin time: Hirudin assessment. Thromb Haemost 1994; 72: 685-92.
20. Schwarz RP, Becker JCP, Brooks RL, Joffrion JL, Knappenherger GD, Kogan TP, Kogan PW, McKinney AA. The prcdinical and clinical pharmacology of Novaslan (argatroban): a small-molecule, direct thrombin inhibitor. Clin Appl Thrombos Hemost 1997; 3: 1-15.
21. Potzsch B, Madlener K, Seelig C, Riess CF, Grcinacher A, Müller-Berghaus G. Monitoring of r-hirudin anticoagulation during eardiopulmonary bypass - Assessment of the whole blood ecarin clotting time. Thromb Haemost 1997; 77: 920-5.
22. Kher A, Al Dieri R, Hemker HC, Beguin S. Laboratory assessment of antithrombotic therapy: what tests and if so why? Haemostasis 1997; 27: 211-8.
23. Herrman JPR, Suryapranata H, den Heijer P, Gabriel L, Kutryk MJB, Serruys PW. Argairoban during percutaneous transluminal coronary angioplasty: results of a dose-verification study. J Thromb Thrombolys 1996; 3: 367-73.
24. Levine MN, Raskob G, Landcfeld S, Kearon C. Hcmorrhagic complications of anticoagulant treatment. Chest 1998; 114: 511S-523S.